Opens in a new tab
Wednesday, 18 November 2026
EVIDENCE. INTERPRETED.
Advertisement · Remove ads
728 × 90
Health Tidings

EMA Update Enables Non-Cold-Chain Final Delivery for Wegovy in Europe

EMA has approved a product information update for Wegovy injection allowing delivery at controlled temperatures up to 30°C for 48 hours, enabling more flexible distribution and expanding home-delivery…

Written byKarthik Teja MacharlaReviewed byPharmacally Editorial Team9 April 2026 · 3 min read
Fact-Checked
68693

EMA approves updated storage guidance for Wegovy injection, allowing delivery at up to 30°C for 48 hours, reducing cold-chain complexity and supporting home delivery options in Europe.

The European Medicines Agency (EMA) has approved an update to the product information for Wegovy injection that allows the medicine to remain at controlled temperatures of up to 30°C for up to 48 hours during delivery. The change reduces distribution complexity and introduces additional flexibility for pharmacies and online partners.

With this update, Wegovy becomes the only GLP-1 therapy for weight management in Europe with this delivery flexibility.

Previously, Wegovy distribution required full cold-chain handling, meaning the medicine had to be kept refrigerated from manufacturing through patient use. Following the EMA decision, the final delivery stage from pharmacies to patients can now occur within a 48-hour window at temperatures up to 30°C. This added flexibility is expected to simplify logistics and support broader delivery options.

The updated guidance may also help expand eHealth and direct-to-patient delivery models across Europe. Reduced reliance on cold-chain transport could lower packaging requirements and decrease shipment weight, potentially improving operational efficiency for distribution partners.

Mike Doustdar, CEO and president of Novo Nordisk, highlighted that home delivery of medicines is increasing due to convenience and patient preference. He noted that people using prescription medicines for obesity may experience stigma and said the added distribution flexibility could enable more discreet home delivery while reducing logistical complexity.

The approval reflects evolving industry practices, including increased use of direct-to-patient distribution models such as online pharmacies and other non-traditional dispensing channels. The update has been incorporated into the Summary of Product Characteristics (SmPC) for healthcare professionals, including physicians and pharmacists.

There is no change to patient instructions. After first use, patients may continue storing Wegovy for up to 28 days at temperatures below 30°C or under refrigeration.

The update applies only to Wegovy injection and not to the oral formulation. The oral version does not require refrigeration, is approved in the United States, and is currently pending a European regulatory decision expected later in 2026.

In the European Union, Wegovy is approved by the European Medicines Agency as a once-weekly subcutaneous semaglutide injection for chronic weight management across multiple dose strengths, including 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and the standard maintenance dose of 2.4 mg for dose escalation and long-term treatment. In addition, the EU has also approved a higher-dose 7.2 mg formulation for patients requiring additional weight-loss efficacy beyond the 2.4 mg regimen. All approved EU presentations are pre-filled injectable pens, while an oral formulation of Wegovy is approved in the United States and remains under regulatory review in Europe, with a decision anticipated later in 2026.

Reference

Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU, 09 April 2026, News Details

Advertisement · Remove ads
728 × 90
Reviewed by the Pharmacally Editorial Team
Every story is checked against primary sources.
Our editorial process →